A brain implant startup called Synchron is preparing to recruit patients for a large-scale clinical trial to seek commercial approval for its device. Reuters reports: Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview. "Part of this registry is to start to enable local physicians to speak to patients with motor impairment," he said. "There's a lot of interest so we don't want it to come in a big bottleneck right before the study we'll be doing." Synchron received U.S. authorization for preliminary testing in July 2021 and has implanted its device in six patients. Prior testing in four patients in Australia showed no serious adverse side effects, the company has reported. Synchron will be analyzing the U.S. data to prepare for the larger study, while awaiting authorization from the U.S. Food and Drug Administration to proceed, Oxley said. Synchron and the FDA declined to comment on the expected timing of that decision. The company aims to include patients who are paralyzed due to the neurodegenerative disease ALS (amyotrophic lateral sclerosis), stroke and multiple sclerosis, Oxley said. [...] Synchron's device is delivered to the brain via the large vein that sits next to the motor cortex in the brain instead of being surgically implanted into the brain cortex like Neuralink's. The FDA has asked Synchron to screen stroke patients using a non-invasive test to determine whether they would respond to an implant, Oxley said. "They want to expand the market to people who have had a stroke severe enough to cause paralysis because if limited to quadriplegia, the market is way too small to be sustainable," Kip Ludwig, former program director for neural engineering at the U.S. National Institutes of Health, said of Synchron. In 2020, Synchron reported that patients, opens new tab in its Australian study could use its first-generation device to type an average of 16 characters per minute. That's better than non-invasive devices that sit atop the head and record the electrical activity of the brain, which have helped people type up to eight characters per minute, but not the leap forward that is hoped for with an implant, Ludwig said. Oxley would not say whether typing has gotten faster or offer any other details from the ongoing U.S. trial. Reuters notes that Synchron's investors include billionaires Jeff Bezos and Bill Gates. It's competing with Elon Musk's Neuralink brain implant startup and claims it's farther along in the process of testing its device. Earlier this year, Neuralink said it implanted a chip in its first human patient. It later said the patient fully recovered and was able to control a computer mouse using their thoughts.

Read more of this story at Slashdot.

An anonymous reader quotes a report from InterestingEngineering: A Pittsburgh-based biotech company has started a one-of-a-kind trial in a patient with a failing liver. Their goal is to grow a functional second liver within the patient's body -- something never achieved before. If effective, it might be a life-saving therapy for those who require liver transplants but have to wait months for a compatible donor organ. LyGenesis is currently carrying out a trial in only one patient with end-stage liver disease (ESLD) to test the efficacy of their allogenic regenerative cell therapy. As per Nature, the experimental procedure was conducted in Houston on March 25. The report also states that the patient is "recovering well" after receiving the treatment. However, the formation of the new liver-like organ in the lymph node may take several months. Moreover, the individual will be kept on immunosuppressive drugs to prevent any initial rejection of the donor cells. The physicians will continue to monitor the patient's health closely. In this trial, scientists prepared donated hepatocyte cells for transplantation by suspending them in a solution. These cells were then transplanted into the patient's upper abdominal lymph nodes, which are tiny bean-shaped structures. These structures are an essential immune system component and filter waste from the body. Apart from the abdomen, lymph nodes are also found in the neck and chest. The team opted for a minimally invasive approach to inject the cells into the patient's lymph node via a catheter in the neck. "The lymph nodes then act as in vivo bioreactors, helping the hepatocytes to engraft, proliferate, and generate functional ectopic liver tissue," the press release noted. In simplest terms, these cells have the ability to multiply over the next several months. In a person with a failing liver, lymph nodes might operate as a second liver-like organ.

Read more of this story at Slashdot.

Neuralink, the brain-chip startup founded by Elon Musk, showed its first patient using his mind to play online chess. Reuters reports: Noland Arbaugh, the 29-year-old patient who was paralyzed below the shoulder after a diving accident, played chess on his laptop and moved the cursor using the Neuralink device. The implant seeks to enable people to control a computer cursor or keyboard using only their thoughts. Arbaugh had received an implant from the company in January and could control a computer mouse using his thoughts, Musk said last month. "The surgery was super easy," Arbaugh said in the video streamed on Musk's social media platform X, referring to the implant procedure. "I literally was released from the hospital a day later. I have no cognitive impairments. I had basically given up playing that game," Arbaugh said, referring to the game Civilization VI, "you all (Neuralink) gave me the ability to do that again and played for 8 hours straight." Elaborating on his experience with the new technology, Arbaugh said that it is "not perfect" and they "have run into some issues." "I don't want people to think that this is the end of the journey, there's still a lot of work to be done, but it has already changed my life," he added.

Read more of this story at Slashdot.

Neuralink, the brain-chip startup founded by Elon Musk, showed its first patient using his mind to play online chess. Reuters reports: Noland Arbaugh, the 29-year-old patient who was paralyzed below the shoulder after a diving accident, played chess on his laptop and moved the cursor using the Neuralink device. The implant seeks to enable people to control a computer cursor or keyboard using only their thoughts. Arbaugh had received an implant from the company in January and could control a computer mouse using his thoughts, Musk said last month. "The surgery was super easy," Arbaugh said in the video streamed on Musk's social media platform X, referring to the implant procedure. "I literally was released from the hospital a day later. I have no cognitive impairments. I had basically given up playing that game," Arbaugh said, referring to the game Civilization VI, "you all (Neuralink) gave me the ability to do that again and played for 8 hours straight." Elaborating on his experience with the new technology, Arbaugh said that it is "not perfect" and they "have run into some issues." "I don't want people to think that this is the end of the journey, there's still a lot of work to be done, but it has already changed my life," he added.

Read more of this story at Slashdot.

"A pet company has twice sent back dog breed results for human swab samples," reports the Guardian, "prompting doubts surrounding the accuracy of dog breed tests." On Wednesday, WBZ News reported its investigations team receiving dog breed results from the company DNA My Dog after one of its reporters sent in a swab sample — from her own cheek. According to the results from the Toronto-based company, WBZ News reporter Christina Hager is 40% Alaskan malamute, 35% shar-pei and 25% labrador. Hager also sent her samples to two other pet genetic testing companies. The Melbourne, Australia- and Florida-based company Orivet reported that the sample "failed to provide the data necessary to perform the breed ID analysis". Meanwhile, Washington-based company Wisdom Panel said that the sample "didn't provide ... enough DNA to produce a reliable result"... The global dog DNA test market, which was valued at $235m in 2022, is projected to grow to $723m by 2030, according to Zion Market Research. The industry's main players include DNA My Dog, Orivet and Wisdom Panel, among others. But faulty results have cast doubt on the accuracy of the DNA tests. Thanks to jd (Slashdot reader #1,658) for sharing the article.

Read more of this story at Slashdot.

An anonymous reader quotes a report from Inside Climate News: Months in jail and thousands of dollars in fines and legal fees -- those are the consequences Alabamians and Arizonans could soon face for selling cell-cultured meat products that could cut into the profits of ranchers, farmers and meatpackers in each state. State legislators from Florida to Arizona are seeking to ban meat grown from animal cells in labs, citing a "war on our ranching" and a need to protect the agriculture industry from efforts to reduce the consumption of animal protein, thereby reducing the high volume of climate-warming methane emissions the sector emits. Agriculture accounts for about 11 percent of the country's greenhouse gas emissions, according to federal data, with livestock such as cattle making up a quarter of those emissions, predominantly from their burps, which release methane -- a potent greenhouse gas that's roughly 80 times more effective at warming the atmosphere than carbon dioxide over 20 years. Globally, agriculture accounts for about 37 percent of methane emissions. For years, climate activists have been calling for more scrutiny and regulation of emissions from the agricultural sector and for nations to reduce their consumption of meat and dairy products due to their climate impacts. Last year, over 150 countries pledged to voluntarily cut emissions from food and agriculture at the United Nations' annual climate summit. But the industry has avoided increased regulation and pushed back against efforts to decrease the consumption of meat, with help from local and state governments across the U.S. Bills in Alabama, Arizona, Florida and Tennessee are just the latest legislation passed in statehouses across the U.S. that have targeted cell-cultured meat, which is produced by taking a sample of an animal's muscle cells and growing them into edible products in a lab. Sixteen states -- Alabama, Arkansas, Georgia, Kansas, Kentucky, Louisiana, Maine, Mississippi, Missouri, Montana, North Dakota, Oklahoma, South Carolina, South Dakota, Texas and Wyoming -- have passed laws addressing the use of the word "meat" in such products' packaging, according to the National Agricultural Law Center at the University of Arkansas, with some prohibiting cell-cultured, plant-based or insect-based food products from being labeled as meat.

Read more of this story at Slashdot.

An anonymous reader shared this article from the Washington Post: A much-debated theory holds that 4 billion years ago, give or take, long before the appearance of dinosaurs or even bacteria, the primordial soup contained only the possibility of life. Then a molecule called RNA took a dramatic step into the future: It made a copy of itself. Then the copy made a copy, and over the course of many millions of years, RNA begot DNA and proteins, all of which came together to form a cell, the smallest unit of life able to survive on its own. Now, in an important advance supporting this RNA World theory, scientists at the Salk Institute for Biological Studies in La Jolla, Calif., have carried out a small but essential part of the story. In test tubes, they developed an RNA molecule that was able to make accurate copies of a different type of RNA. The work, published in the journal Proceedings of the National Academy of Sciences, gets them closer to the grand goal of growing an RNA molecule that makes accurate copies of itself. "Then it would be alive," said Gerald Joyce, president of Salk and one of the authors of the new paper. "So, this is the road to how life can arise in a laboratory or, in principle, anywhere in the universe...." John Chaput, a professor of pharmaceutical sciences at the University of California at Irvine who did not participate in the study, called the crossing of that threshold by the Salk team "monumental," adding that "at first, I looked on it as a little bit jaw-dropping. ... It's super-neat." The Post adds that "the scenario they tested probably mimics one of the earliest stirrings of evolution." And Michael Kay, a professor of biochemistry at University of Utah, says the new paper has given the RNA World theory "key evidence" to show "it is plausible and reasonable." He added that the RNA copier developed at Salk will "provide a valuable tool for people wanting to do directed evolution experiments."

Read more of this story at Slashdot.

Mexico is waiting for the United States to provide evidence that shows imported genetically modified corn is safe for human consumption. "In a written submission to a panel of the United States-Mexico-Canada Agreement, Mexico, the top buyer of U.S. corn, argued that science proves GM corn and the herbicide glyphosate are harmful to human health and its native varieties, and that its decree to ban GM corn for human consumption is within its right," reports Reuters. From the report: [Deputy Agriculture Secretary Victor Suarez] said the onus is now on the United States to show GM corn is not harming Mexico's population, which consumes a higher amount of corn than many countries through daily diet staples like nixtamalized dough and tortilla. The United States "argues that the decisions in Mexico are not based on science and that their decisions are," Suarez told Reuters in an interview. "But we still haven't seen the science of the United States or the companies. We are looking forward to that study with great pleasure." A spokesman for the U.S. Department of Agriculture said Mexico's approach to biotechnology runs counter to "decades' worth of evidence demonstrating its safety." A senior official for the U.S. Trade Representative said, "Scientific authorities, including in Mexico, have consistently found biotech products like corn to be safe over a period of decades." [...] Mexico's written response cited studies it said showed links between GM corn consumption and glyphosate exposure to liver inflammation in people and impacts to immune response in animals, saying it considers the risk to human health "extremely serious." The United States in August requested a dispute settlement panel under the USMCA over Mexico's decree to ban GM corn for human consumption, specifically in the use of making flour for tortillas. The decree allows the use of GM yellow corn in animal feed, which accounts for the majority of Mexico's nearly $5.9 billion worth of U.S. corn imports annually. Washington argues Mexico's decree banning imports of GM corn used for tortillas is not based on science and violates its commitments under the USMCA, which has been in place since 2020. "There is no impact on trade," Suarez said of Mexico's decree. "The value and volume of exports of GM corn to Mexico has increased." Mexico's decree also calls for the gradual substitution of GM corn, a point of contention highlighted by U.S. officials. In its written response, Mexico argued that no specific time frame has been established and therefore it has had no trade impact. "It is a strategic goal, like the United States would like to have energy sovereignty and energy self-sufficiency," Suarez said. The United States is expected to issue a rebuttal to Mexico's response.

Read more of this story at Slashdot.